{
    "clinical_study": {
        "@rank": "53762", 
        "arm_group": [
            {
                "arm_group_label": "aspirn fixed dose", 
                "arm_group_type": "Placebo Comparator", 
                "description": "patients of this arm will receive 100 mg of aspirin daily.over the period of follow up we will detect all thromboembolic events."
            }, 
            {
                "arm_group_label": "aspirin dose titrated with PFA-100", 
                "arm_group_type": "Placebo Comparator", 
                "description": "patients of this arm will receive 100 mg of aspirin daily.this dose will be multiplied whenever the PFA-100 is not suitable.once the time of occlusion is correct ,we will keep the same dose of aspirin and continue monitoring the PFA-100 durin the follow up period."
            }, 
            {
                "arm_group_label": "placebo arm", 
                "arm_group_type": "No Intervention", 
                "description": "in this group of patients we will just supervise thromboembolic events of the vascular access."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective  study consisting in testing whether systematic use of aspirin is\n      beneficial for primary prevention of vascular access for hemodialysis attested by doppler\n      ultrasound exam. The investigators will study aspirin resistance in the population of\n      patients undergoing hemodialysis.  The investigators will test sensibility of  resistant\n      patients to aspirin dose escalation. PFA-100 is the biologic test used in this study to\n      define aspirin resistance."
        }, 
        "brief_title": "Antiaggregation in Primary Prevention of Vascular Access for Hemodialysis", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Thrombosis", 
        "condition_browse": {
            "mesh_term": "Thrombosis"
        }, 
        "detailed_description": {
            "textblock": "Three groups of dialysed patients will be included in this study. The first is the placebo\n      group, the second is  the aspirin group fixed dose and the last group includes patients\n      receiving a dose of aspirin titrated by the result of PFA-100.\n\n      At the end of this study the investigators will be able to identify whether systematic\n      antiaggregation is suitable for a vascular access for hemodialysis. The investigators will\n      also conclude which is better for patients fixed dose or aspirin dose escalation determined\n      by the result of PFA-100. The study will analyse the prevalence of aspirin resistant\n      patients in this particular population of dialysed patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  dialysed patients\n\n          -  vascular access aged less than one year\n\n          -  no serious complication of the vascular access previously such as hemorrhagic\n             complication and tight stenosis\n\n        Exclusion Criteria:\n\n          -  pregnant and breastfeeding women\n\n          -  patients receiving at baseline other antiaggregant or anticoagulant\n\n          -  patient not allowed to be treated by aspirin\n\n          -  systolic blood pressure> 200 mmhg\n\n          -  diastolic blood pressure>115 mmhg\n\n          -  liver failure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02055131", 
            "org_study_id": "913"
        }, 
        "intervention": {
            "arm_group_label": [
                "aspirn fixed dose", 
                "aspirin dose titrated with PFA-100"
            ], 
            "intervention_name": "aspirin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Aspirin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "vascular access", 
            "hemodialysis", 
            "aspirin resistance", 
            "PFA-100"
        ], 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "contact": {
                "email": "manell_bs@hotmail.com", 
                "last_name": "Manel Ben Salah, nephrologist", 
                "phone": "+216 55 928 869"
            }, 
            "contact_backup": {
                "email": "alouisabra@yahoo.fr", 
                "last_name": "Sabra Aloui, professor", 
                "phone": "+216 92453822"
            }, 
            "facility": {
                "address": {
                    "city": "Monastir", 
                    "country": "Tunisia", 
                    "zip": "5000"
                }, 
                "name": "clinical and medical investigation in emergency medecine laboratry,hospitalo-university center of Monastir"
            }, 
            "investigator": [
                {
                    "last_name": "asma fradi, assistant", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Manel Ben Salah, nephrologist", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Sabra Aloui, professor", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Tunisia"
        }, 
        "number_of_arms": "3", 
        "official_title": "a Comparative Study of Aspirin Either at Fixed Dose or at a Dose Titrated by Platlet Function Analyzer(PFA-100) vs Placebo in Primary Prevention of Vascular Access for Hemodialysis", 
        "other_outcome": {
            "measure": "incidence and severity of aspirin complications in dialysed patients", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "overall_official": {
            "last_name": "Nouira Samir, professor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Tunisia:health ministry", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "patients undergoing hemodialysis via native fistula will receive either placebo or aspirin titrated dose by the PFA-100 or aspirin fixed dose to prevent thrombosis of the access .the follow up period will be fixed at 1 year and all thromboembolic complications of the access will be noted", 
            "measure": "number of fistula thrombosis in patients receiving a dose of aspirin titrated by the result of PFA-100 compared to placebo and fixed dose aspirin", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02055131"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tunis University", 
            "investigator_full_name": "Ben Salah Manel", 
            "investigator_title": "nephrologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "number of aspirin resistant patients even to aspirin escalation dose titrated by PFA-100 in the population of dialysed patients.", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "Tunis University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tunis University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}